Framatome and Nuclearelectrica to produce Lutetium‑177 in Romania

Framatome and SN Nuclearelectrica SA (SNN) have signed a cooperation agreement to implement the IRIS Project for production of Lutetium‑177 medical radioisotopes at the Cernavoda nuclear power plant, targeting commercial service launch in 2028.

• Main announcement: The agreement establishes a collaboration framework in which Framatome and SNN will implement production of Lutetium‑177, operate the equipment and infrastructure resulting from the project at Cernavoda nuclear power plant, and explore future radioisotope projects; the IRIS Project entered effective implementation and aims for commercial service in 2028.
• Background and details: The companies highlighted 2025 as a key year for project development; the release states global and regional demand context: >10,000 medical care units worldwide, ~49 million radioisotope procedures/year globally, and >1,500 medical care units in the EU (~10 million procedures/year); CEOs Grégoire Ponchon (Framatome) and Cosmin Ghita (Nuclearelectrica) provided quoted commitments.